Rewind Therapeutics welcomes Sunstone Life Science Ventures A/S as New Investor. We are delighted to welcome Sunstone Life Science Venture as a new investor alongside the continued support by our existing investor syndicate. The additional financing not only strengthens our top-tier investor base, but also allows us to accelerate the progression of our lead program into clinical development. In addition, we look forward to working with an experienced investor as Claus Andersson as a new member of our Board of Directors. Learn more about Sunstone Life Science Ventures at https://lnkd.in/eMzM_yUn #neurodegeneration #myelination
About us
Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury. There is no cure for demyelinating diseases. The Company was founded by KU Leuven’s Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. (Milano, Italy), a leading provider of integrated discovery services for the Life Sciences. Rewind Therapeutics works in close collaboration with both organisations and a world-class academic network to advance its discovery and development activities. Rewind Therapeutics is backed by life science investors Boehringer Ingelheim Venture Fund, M Ventures and the Flemish investment company PMV, together with CD3 and KU Leuven Gemma Frisius Fonds.
- Website
-
http://rewindtherapeutics.com
External link for Rewind Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Heverlee, Flemish Region
- Type
- Privately Held
- Founded
- 2017
- Specialties
- biotech, myelin, therapy, and multiple sclerosis
Locations
-
Primary
Get directions
Gaston Geenslaan
Heverlee, Flemish Region 3001, BE
Employees at Rewind Therapeutics
-
Claus Andersson
General Partner, PhD, Life Science Venture Capital
-
Jim Van heusden
Entrepreneur - CEO - Board Professional - Change Management - Managing Director bioskills
-
Guillaume Duvey
VP Drug Discovery at Rewind Therapeutics - Biotech Entrepreneur & Advisor
-
Stephen Burbidge
Experienced Leader; Discovery and Early Development; Biotech, Pharma and Consultancy
Updates
-
Congratulations to Guillaume Duvey on the promotion to VP Drug Discovery. Guillaume has been an integral part of our team, demonstrating exceptional dedication, innovative thinking, and outstanding performance to identify remyelinating therapies. In light of Guillaume’s promotion and expanded remit, Stephen Burbidge, as VP Preclinical Drug Development, will now focus on Rewind’s preclinical development activities moving our compounds towards clinical trials. #RewindTherapeutics #Remylination #DrugDiscovery #DrugDevelopment
-
-
Rewind Therapeutics reposted this
Rewind Therapeutics is #hiring. Interested in an opportunity to join a talented team developing remyelinating therapies for CNS disorders?